Inhibitors ofmicrosomal prostaglandin (PG) E synthase-1 (mPGES-1) are being developed for the relief of pain. Redirection of the PGH2 substrate to other PG synthases, found both in vitro and in vivo, in mPGES-1 knockoutmice, may influence their efficacy and safety.We characterized the contribution ofmPGES-1 to PGH2metabolism in lipopolysaccharide (LPS)-stimulated isolated human monocytes and whole blood by studying the synthesis of prostanoids [PGE2, thromboxane (TX)B2, PGF2a and 6-keto-PGF1a] and expression of cyclooxygenase (COX)-isozymes and down-stream synthases in the presence of pharmacological inhibition by the novel mPGES-1 inhibitor AF3442 [N-(9-ethyl-9H-carbazol-3-yl)- 2- (trifluoromethyl)benzamide]. AF3442 caused a concentration-dependent inhibition of PGE2 in human recombinant mPGES-1 with an IC50 of 0.06 mM. In LPS-stimulated monocytes, AF3442 caused a concentration-dependent reduction of PGE2 biosynthesis with an IC50 of 0.41 mM. At 1 mM, AF3442 caused maximal selective inhibitory effect of PGE2 biosynthesis by 61 ± 3.3% (mean ± SEM, P < 0.01 versus DMSO vehicle) without significantly affecting other prostanoids (i.e. TXB2, PGF2α and 6-keto-PGF17alpha;). In LPS-stimulated whole blood, AF3442 inhibited in a concentration-dependent fashion inducible PGE2 biosynthesis with an IC 50 of 29 μM. A statistically significant inhibition of mPGES-1 activity was detected at 10 and 100 μM(38 ± 14%, P < 0.05, and 69 ± 5%, P < 0.01, respectively). Up to 100 mM, the other prostanoids were not significantly affected. In conclusion, AF3442 is a selective mPGES-1 inhibitor which reduced monocyte PGE2 generation also in the presence of plasma proteins. Pharmacological inhibition of mPGES-1 did not translate into redirection of PGH2 metabolismtowards other terminal PG synthases in monocytes. The functional relevance of this observation deserves to be investigated in vivo.
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro.
BRUNO, ANNALISA;RICCIOTTI, EMANUELA;DOVIZIO, MELANIA;TACCONELLI, Stefania;CAPONE, Marta Luciana;PATRIGNANI, Paola
2010-01-01
Abstract
Inhibitors ofmicrosomal prostaglandin (PG) E synthase-1 (mPGES-1) are being developed for the relief of pain. Redirection of the PGH2 substrate to other PG synthases, found both in vitro and in vivo, in mPGES-1 knockoutmice, may influence their efficacy and safety.We characterized the contribution ofmPGES-1 to PGH2metabolism in lipopolysaccharide (LPS)-stimulated isolated human monocytes and whole blood by studying the synthesis of prostanoids [PGE2, thromboxane (TX)B2, PGF2a and 6-keto-PGF1a] and expression of cyclooxygenase (COX)-isozymes and down-stream synthases in the presence of pharmacological inhibition by the novel mPGES-1 inhibitor AF3442 [N-(9-ethyl-9H-carbazol-3-yl)- 2- (trifluoromethyl)benzamide]. AF3442 caused a concentration-dependent inhibition of PGE2 in human recombinant mPGES-1 with an IC50 of 0.06 mM. In LPS-stimulated monocytes, AF3442 caused a concentration-dependent reduction of PGE2 biosynthesis with an IC50 of 0.41 mM. At 1 mM, AF3442 caused maximal selective inhibitory effect of PGE2 biosynthesis by 61 ± 3.3% (mean ± SEM, P < 0.01 versus DMSO vehicle) without significantly affecting other prostanoids (i.e. TXB2, PGF2α and 6-keto-PGF17alpha;). In LPS-stimulated whole blood, AF3442 inhibited in a concentration-dependent fashion inducible PGE2 biosynthesis with an IC 50 of 29 μM. A statistically significant inhibition of mPGES-1 activity was detected at 10 and 100 μM(38 ± 14%, P < 0.05, and 69 ± 5%, P < 0.01, respectively). Up to 100 mM, the other prostanoids were not significantly affected. In conclusion, AF3442 is a selective mPGES-1 inhibitor which reduced monocyte PGE2 generation also in the presence of plasma proteins. Pharmacological inhibition of mPGES-1 did not translate into redirection of PGH2 metabolismtowards other terminal PG synthases in monocytes. The functional relevance of this observation deserves to be investigated in vivo.File | Dimensione | Formato | |
---|---|---|---|
Bruno et al BP 2010.pdf
Solo gestori archivio
Tipologia:
PDF editoriale
Dimensione
435.97 kB
Formato
Adobe PDF
|
435.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.